NO332446B1 - Peptid, farmasoytisk preparat samt anvendelse av peptidet - Google Patents
Peptid, farmasoytisk preparat samt anvendelse av peptidet Download PDFInfo
- Publication number
- NO332446B1 NO332446B1 NO20043210A NO20043210A NO332446B1 NO 332446 B1 NO332446 B1 NO 332446B1 NO 20043210 A NO20043210 A NO 20043210A NO 20043210 A NO20043210 A NO 20043210A NO 332446 B1 NO332446 B1 NO 332446B1
- Authority
- NO
- Norway
- Prior art keywords
- peptide
- peptides
- cell
- antigen
- epitopes
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 150
- 239000000825 pharmaceutical preparation Substances 0.000 title claims description 14
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 61
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 claims abstract description 39
- 102000047918 Myelin Basic Human genes 0.000 claims abstract description 37
- 101710107068 Myelin basic protein Proteins 0.000 claims abstract description 37
- 238000012545 processing Methods 0.000 claims abstract description 17
- 102000043129 MHC class I family Human genes 0.000 claims abstract description 10
- 108091054437 MHC class I family Proteins 0.000 claims abstract description 10
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 claims abstract description 7
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 claims abstract description 6
- 201000006417 multiple sclerosis Diseases 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 230000003614 tolerogenic effect Effects 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 14
- 201000010099 disease Diseases 0.000 abstract description 13
- 238000000034 method Methods 0.000 abstract description 12
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 65
- 239000000427 antigen Substances 0.000 description 41
- 108091007433 antigens Proteins 0.000 description 40
- 102000036639 antigens Human genes 0.000 description 40
- 210000004027 cell Anatomy 0.000 description 27
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 20
- 210000000612 antigen-presenting cell Anatomy 0.000 description 20
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 20
- 230000030741 antigen processing and presentation Effects 0.000 description 12
- 108010002350 Interleukin-2 Proteins 0.000 description 11
- 230000004044 response Effects 0.000 description 11
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 10
- 150000001413 amino acids Chemical group 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 6
- 229940104230 thymidine Drugs 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 5
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 4
- 108091008874 T cell receptors Proteins 0.000 description 4
- 230000005867 T cell response Effects 0.000 description 4
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 4
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 208000026935 allergic disease Diseases 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 108091054438 MHC class II family Proteins 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 102000043131 MHC class II family Human genes 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 102000007079 Peptide Fragments Human genes 0.000 description 2
- 108010033276 Peptide Fragments Proteins 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- 230000006052 T cell proliferation Effects 0.000 description 2
- 230000033289 adaptive immune response Effects 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000005784 autoimmunity Effects 0.000 description 2
- 230000000981 bystander Effects 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000001516 cell proliferation assay Methods 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000013630 prepared media Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 210000004885 white matter Anatomy 0.000 description 2
- WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 108010051539 HLA-DR2 Antigen Proteins 0.000 description 1
- 101001018318 Homo sapiens Myelin basic protein Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 102100037611 Lysophospholipase Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010058864 Phospholipases A2 Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 230000017274 T cell anergy Effects 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000006470 autoimmune attack Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000003659 bee venom Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 230000004940 costimulation Effects 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003210 demyelinating effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000001712 encephalitogenic effect Effects 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 1
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 102000054064 human MBP Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000017307 interleukin-4 production Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000009696 proliferative response Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229960002385 streptomycin sulfate Drugs 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 208000034280 venom allergy Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Rehabilitation Therapy (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0202399.2A GB0202399D0 (en) | 2002-02-01 | 2002-02-01 | Peptide |
PCT/GB2003/000399 WO2003064464A1 (en) | 2002-02-01 | 2003-01-30 | Tolerogenic peptides from myelin basic protein |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20043210L NO20043210L (no) | 2004-11-01 |
NO332446B1 true NO332446B1 (no) | 2012-09-17 |
Family
ID=9930251
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20043210A NO332446B1 (no) | 2002-02-01 | 2004-07-28 | Peptid, farmasoytisk preparat samt anvendelse av peptidet |
Country Status (24)
Country | Link |
---|---|
US (1) | US7071297B2 (pt) |
EP (1) | EP1474443B1 (pt) |
JP (1) | JP4559082B2 (pt) |
KR (1) | KR20040108650A (pt) |
CN (1) | CN100482685C (pt) |
AT (1) | ATE477269T1 (pt) |
AU (1) | AU2003202701B2 (pt) |
BR (1) | BRPI0307276B8 (pt) |
CA (1) | CA2473469C (pt) |
CO (1) | CO5601035A2 (pt) |
CY (1) | CY1110862T1 (pt) |
DE (1) | DE60333728D1 (pt) |
DK (1) | DK1474443T3 (pt) |
ES (1) | ES2349463T3 (pt) |
GB (1) | GB0202399D0 (pt) |
HK (1) | HK1066551A1 (pt) |
MX (1) | MXPA04007510A (pt) |
NO (1) | NO332446B1 (pt) |
NZ (1) | NZ534233A (pt) |
PL (1) | PL212129B1 (pt) |
PT (1) | PT1474443E (pt) |
SI (1) | SI1474443T1 (pt) |
WO (1) | WO2003064464A1 (pt) |
ZA (1) | ZA200405546B (pt) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU229377B1 (hu) | 2000-08-21 | 2013-11-28 | Apitope Technology Bristol Ltd | Tolerogén humán peptidek |
WO2008121836A1 (en) * | 2007-03-30 | 2008-10-09 | Brigham And Women's Hospital, Inc. | Compounds and methods for enhancing mhc class ii therapies |
US8623827B2 (en) | 2007-10-31 | 2014-01-07 | Apitope Technology (Bristol) Limited | Myelin basic protein peptide composition |
CA2780961C (en) | 2009-10-12 | 2018-10-02 | Lifebio Laboratories Llc | Composition for treatment of multiple sclerosis |
US9850296B2 (en) | 2010-08-10 | 2017-12-26 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
US9517257B2 (en) | 2010-08-10 | 2016-12-13 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
WO2012021512A2 (en) | 2010-08-10 | 2012-02-16 | Ecole Polytechnique Federale De Lausanne | Erythrocyte-binding therapeutics |
GB201314052D0 (en) | 2013-08-06 | 2013-09-18 | Apitope Int Nv | Peptides |
AU2015233084B2 (en) | 2014-02-21 | 2020-12-17 | Anokion Sa | Glycotargeting therapeutics |
US10046056B2 (en) | 2014-02-21 | 2018-08-14 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
US10946079B2 (en) | 2014-02-21 | 2021-03-16 | Ecole Polytechnique Federale De Lausanne | Glycotargeting therapeutics |
US10953101B2 (en) | 2014-02-21 | 2021-03-23 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
CN107249617A (zh) * | 2014-12-24 | 2017-10-13 | 艾匹托普国际股份有限公司 | 组合物 |
EP3344575B1 (en) | 2015-09-04 | 2020-04-15 | SQZ Biotechnologies Company | Intracellular delivery of biomolecules to cells comprising a cell wall |
WO2018127828A1 (en) * | 2017-01-04 | 2018-07-12 | Apitope International Nv | Therapeutic method using tolerogenic peptides |
EP3638296A1 (en) | 2017-06-16 | 2020-04-22 | The University Of Chicago | Compositions and methods for inducing immune tolerance |
CN110317254A (zh) * | 2018-03-28 | 2019-10-11 | 深圳市安群生物工程有限公司 | 人mbp抗原表位肽、抗原、抗体、应用及化学发光试剂盒 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996012737A2 (en) * | 1994-10-25 | 1996-05-02 | Immulogic Pharmaceutical Corporation | Compositions and treatment for multiple sclerosis |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5858980A (en) * | 1990-03-30 | 1999-01-12 | Autoimmune, Inc. | Peptide fragments of myelin basic protein |
AU2470595A (en) * | 1994-05-10 | 1995-11-29 | Immulogic Pharmaceutical Corporation | Compositions and treatment for multiple sclerosis |
HU229377B1 (hu) * | 2000-08-21 | 2013-11-28 | Apitope Technology Bristol Ltd | Tolerogén humán peptidek |
-
2002
- 2002-02-01 GB GBGB0202399.2A patent/GB0202399D0/en not_active Ceased
-
2003
- 2003-01-30 BR BRPI0307276A patent/BRPI0307276B8/pt not_active IP Right Cessation
- 2003-01-30 SI SI200331890T patent/SI1474443T1/sl unknown
- 2003-01-30 DE DE60333728T patent/DE60333728D1/de not_active Expired - Lifetime
- 2003-01-30 CA CA2473469A patent/CA2473469C/en not_active Expired - Lifetime
- 2003-01-30 PT PT03701612T patent/PT1474443E/pt unknown
- 2003-01-30 AU AU2003202701A patent/AU2003202701B2/en not_active Ceased
- 2003-01-30 ES ES03701612T patent/ES2349463T3/es not_active Expired - Lifetime
- 2003-01-30 KR KR10-2004-7011906A patent/KR20040108650A/ko not_active Application Discontinuation
- 2003-01-30 WO PCT/GB2003/000399 patent/WO2003064464A1/en active Application Filing
- 2003-01-30 EP EP03701612A patent/EP1474443B1/en not_active Expired - Lifetime
- 2003-01-30 AT AT03701612T patent/ATE477269T1/de active
- 2003-01-30 NZ NZ534233A patent/NZ534233A/en not_active IP Right Cessation
- 2003-01-30 PL PL371549A patent/PL212129B1/pl unknown
- 2003-01-30 MX MXPA04007510A patent/MXPA04007510A/es active IP Right Grant
- 2003-01-30 JP JP2003564084A patent/JP4559082B2/ja not_active Expired - Fee Related
- 2003-01-30 DK DK03701612.8T patent/DK1474443T3/da active
- 2003-01-30 CN CNB038030772A patent/CN100482685C/zh not_active Expired - Fee Related
-
2004
- 2004-07-13 ZA ZA2004/05546A patent/ZA200405546B/en unknown
- 2004-07-27 US US10/900,032 patent/US7071297B2/en not_active Expired - Lifetime
- 2004-07-28 NO NO20043210A patent/NO332446B1/no not_active IP Right Cessation
- 2004-08-26 CO CO04083647A patent/CO5601035A2/es not_active Application Discontinuation
- 2004-11-27 HK HK04109379.8A patent/HK1066551A1/xx not_active IP Right Cessation
-
2010
- 2010-10-27 CY CY20101100972T patent/CY1110862T1/el unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996012737A2 (en) * | 1994-10-25 | 1996-05-02 | Immulogic Pharmaceutical Corporation | Compositions and treatment for multiple sclerosis |
Non-Patent Citations (1)
Title |
---|
A.B.VOGT et al., Ligand Motifs of HLA-DRB5*0101 and DRB1*1501 Molecules Delineated from Self-Peptides, Journal of Immunology, 1999, Vol.153 (4), s. 1665-1673, Dated: 01.01.0001 * |
Also Published As
Publication number | Publication date |
---|---|
AU2003202701B2 (en) | 2009-01-08 |
CO5601035A2 (es) | 2006-01-31 |
JP4559082B2 (ja) | 2010-10-06 |
CA2473469C (en) | 2012-04-24 |
PT1474443E (pt) | 2010-10-26 |
EP1474443A1 (en) | 2004-11-10 |
BRPI0307276B8 (pt) | 2021-05-25 |
SI1474443T1 (sl) | 2010-12-31 |
BRPI0307276B1 (pt) | 2019-08-13 |
CN1625564A (zh) | 2005-06-08 |
JP2005531497A (ja) | 2005-10-20 |
CA2473469A1 (en) | 2003-08-07 |
PL371549A1 (en) | 2005-06-27 |
BR0307276A (pt) | 2004-12-14 |
WO2003064464A1 (en) | 2003-08-07 |
HK1066551A1 (en) | 2005-03-24 |
GB0202399D0 (en) | 2002-03-20 |
MXPA04007510A (es) | 2005-07-13 |
PL212129B1 (pl) | 2012-08-31 |
CN100482685C (zh) | 2009-04-29 |
DK1474443T3 (da) | 2010-10-18 |
ZA200405546B (en) | 2005-09-28 |
ES2349463T3 (es) | 2011-01-03 |
US7071297B2 (en) | 2006-07-04 |
KR20040108650A (ko) | 2004-12-24 |
NO20043210L (no) | 2004-11-01 |
NZ534233A (en) | 2006-04-28 |
US20050058643A1 (en) | 2005-03-17 |
ATE477269T1 (de) | 2010-08-15 |
CY1110862T1 (el) | 2015-06-10 |
DE60333728D1 (de) | 2010-09-23 |
EP1474443B1 (en) | 2010-08-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2420949C (en) | Peptide selection method | |
AU2001278637A1 (en) | Peptide selection method | |
NO332446B1 (no) | Peptid, farmasoytisk preparat samt anvendelse av peptidet | |
AU2003202701A1 (en) | Tolerogenic peptides from myelin basic protein | |
JP6347065B2 (ja) | ペプチド | |
AU2006203165B2 (en) | Peptide selection method | |
Shen et al. | Characterization of the dominant autoreactive T-cell epitope in spontaneous autoimmune haemolytic anaemia of the NZB mouse | |
ZA200300881B (en) | Peptide selection method. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: WORG PHARMACEUTICALS (HANGZHOU) CO., CN |
|
MM1K | Lapsed by not paying the annual fees |